cyclophosphamidecyclophosphamide will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Aspect	Description	Notes	Source
Purpose	To delay ejaculation and improve control	Not approved specifically for PE	Clinical trials, drug info
Common Dosage Options	10 mg, 20 mg	Taken 30-60 mins before activity	Medical guidelines
Approved Indications	Erectile dysfunction, sometimes PE off-label	Not FDA-approved exclusively for PE	Medical references
Availability	Over-the-counter (some regions), prescription required	Varies by country	Pharmacology sources

cyclophosphamide will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. danazoldanazol will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Publication types

In Germany, the costs of these medications aren't covered by statutory health insurers because they are categorized as “lifestyle drugs,” meaning that they don’t meet the legal requirements for reimbursement.

Basic questions to ask your doctor

Can a person take tadalafil daily?

danazol will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	60mg	270 + 10 Pills	443.96€ 422.82€
Cialis Generic	5mg	30 + 4 Pills	53.56€ 51.01€
Cialis Generic	60mg	20 Pills	65.61€ 62.49€
Cialis Generic	60mg	60 + 4 Pills	145.06€ 138.15€
Cialis Generic	5mg	20 Pills	41.99€ 39.99€
Tadalista Super Active	20mg	10 Pills	55.64€ 52.99€
Cialis Generic	40mg	120 + 8 Pills	206.98€ 197.12€
Cialis Generic	5mg	60 + 4 Pills	86.02€ 81.92€
Tadalista Super Active	20mg	30 + 6 Pills	128.09€ 121.99€
Cialis Generic	10mg	180 + 8 Pills	236.88€ 225.60€
Cialis Generic	10mg	270 + 10 Pills	308.71€ 294.01€
Cialis Generic	20mg	360 + 10 Pills	427.34€ 406.99€
Cialis Generic	40mg	20 Pills	59.47€ 56.64€
Cialis Generic	60mg	180 + 10 Pills	313.11€ 298.20€

drospirenonedrospirenone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. drospirenone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. larotrectiniblarotrectinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Dosing & Uses

Compared with placebo, IIEF-OF, Q9, and Q10 decreased significantly with tamsulosin (all P < 0.05). The IIEF-IS and OS increased significantly at end point with tadalafil (both P < 0.001); for tamsulosin, change was not significant for IS, while OS decreased significantly (P = 0.009). The IIEF-EF domain increased significantly vs. placebo with tadalafil (P < 0.001) but not tamsulosin (P = 0.699). Conclusions: Tadalafil 5 mg once daily significantly improved ejaculation and orgasm, intercourse and overall satisfaction, and erectile function.

Dosage for benign prostatic hyperplasia (BPH)

Men receiving tamsulosin 0.4 mg once daily experienced a decrease in both ejaculatory/orgasmic frequency and overall satisfaction vs. placebo, with no significant effect on erectile function. A service of the National Library of Medicine, National Institutes of Health. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. Medications that are swallowed or applied to the skin can delay ejaculation by a few minutes.

Full Text Sources

These treatments are considered if premature ejaculation has become a major problem. Both types of medication can have side effects too. Some men already have an orgasm before penetration or shortly afterwards. If this happens almost all the time and becomes a problem for a man, it is considered to be premature ejaculation. The treatment options are medications that can be swallowed or that can be applied to the tip of the penis (glans). larotrectinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Proper Use

ranolazineranolazine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Ranolazine may theoretically increase plasma concentrations of CYP3A4 substrates, such as tadalafil.

Combining tadalafil with other PE medications should be supervised.
It’s important to consider lifestyle factors alongside medication.
Tadalafil can sometimes cause nasal congestion.
Regular medical check-ups are advisable during use.
The medication may improve overall sexual satisfaction.
Not recommended for men with certain cardiovascular conditions.

ranolazine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Visual field defect, retinal vein occlusion, retinal artery occlusion, and non–arteritic anterior ischemic optic neuropathy (NAION) Hypersensitivity, including Stevens-Johnson syndrome and exfoliative dermatitis Guanylate cyclase (sGC) stimulators (eg, riociguat); concomitant use can cause hypotension Coadministration with nitrates (either regularly and/or intermittently) and nitric oxide donors Do not use nitrates within 48 hr of the last dose of macitentan/tadalafil This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway The potentiation is consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway Use caution in patients with anatomic deformation of penis, cardiovascular disease, left ventricular outflow obstruction, myocardial infarction in preceding 90 days, unstable angina, angina occurring during sexual intercourse, NYHA class 2 or greater heart failure in preceding 6 months, uncontrolled arrhythmias, hypotension, uncontrolled hypertension, cerebrovascular accident in preceding 6 months, bleeding disorders, active peptic ulcer disease, liver disease, renal impairment, conditions predisposing to priapism, concomitant use of CYP3A4 inhibitors May cause dose-related impairment of color discrimination; use caution in patients with retinitis pigmentosa Evaluate underlying causes of erectile dysfunction or BPH before initiating therapy Do not use nitrates within 48 hours of last dose of tadalafil Drug has vasodilatory properties that may result in transient decreases in blood pressure; prior to prescribing, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects; patients with preexisting hypotension, with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to actions of vasodilators When used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, reported postmarketing; if vision problems arise, discontinue, and contact physician CYP3A4 inhibitors (eg, erythromycin, ketoconazole, itraconazole, indinavir, ritonavir) may significantly increase tadalafil serum levels CYP3A4 inducers (eg, rifampin, St John’s wort) may decrease tadalafil serum levels Potentiates hypotensive effect of nitrates (see Contraindications) Concomitant use with alpha blockers (other than tamsulosin 0.4 mg/day) should be stabilized before initiation of phosphodiesterase (PDE)-5 inhibitors; patients with instability on alpha-blocker therapy alone are at increased risk for symptomatic hypotension with concurrent PDE-5 inhibitor therapy Not to be taken with other PDE-5 inhibitors (eg, sildenafil, vardenafil) Not recommended in patients with pulmonary veno-occlusive disease Advise patients to seek emergency treatment if an erection lasts >4 hr Limited data from case series with use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes Pregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death In animal reproduction studies, no adverse developmental effects were observed with oral administration to pregnant rats or mice during organogenesis at exposures 7 times the exposure at maximum recommended human dose (MRHD) of 40 mg/day based on AUC There are no data on presence of drug and/or its metabolites in human milk, effects on breastfed child, or on milk production; drug and/or its metabolites are present in milk of lactating rats at concentrations approximately 2.4-times that found in the plasma; when a drug is present in animal milk, it is likely that the drug will be present in human milk Controlled studies in pregnant women show no evidence of fetal risk. Erectile dysfunction: Inhibits PDE-5, increasing cyclic guanosine monophosphate (cGMP) to allow smooth-muscle relaxation and inflow of blood into corpus cavernosum Pulmonary arterial hypertension (PAH): Inhibits PDE-5, increasing cGMP to allow relaxation of pulmonary vascular smooth-muscle cells and vasodilation of pulmonary vasculature Peak plasma time: Erectile dysfunction, 0.5-6 hr; PAH, 2-8 hr Vd: Erectile dysfunction, 63 L; PAH, 77 L Half-life: Erectile dysfunction, 15-17.5 hr; PAH (not on bosentan), 35 hr Total body clearance: Erectile dysfunction, 2.5 L/hr; PAH (not on bosentan), 1.6 L/hr Erectile dysfunction (PRN use): Take before anticipated sexual activity Erectile dysfunction (once-daily use): Take at approximately same time each day without regard to timing of sexual activity Shake well for 30 seconds before measuring dose Take with or without food or water Do not split or break a chewable tablet because this may result in a dose below the minimum therapeutic dose or greater than the maximum recommended dose, which may increase risk of adverse effects Tablets, chewable tablet, oral suspension: Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF) Adding plans allows you to compare formulary status to other drugs in the same class. To view formulary information first create a list of plans. Your list will be saved and can be edited at any time. View the formulary and any restrictions for each plan. Manage and view all your plans together – even plans in different states.

Tadalafil’s off-label use for PE requires medical guidance.
Some men report increased control with tadalafil.
It can be part of a comprehensive PE treatment plan.
Tadalafil may influence psychological aspects of PE.
The medication is not a cure but may help manage symptoms.
Risk factors like heart disease should be assessed before use.

Compare formulary status to other drugs in the same class. Access your plan list on any device – mobile or desktop. Introduction: Tadalafil, a long-acting phosphodiesterase type 5 inhibitor, is approved for treating signs and symptoms of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED); tamsulosin, an alpha-blocker, is approved for treating signs and symptoms of BPH. Aim: To determine the effects of tadalafil or tamsulosin on sexual function, including ejaculation and orgasm, satisfaction, and erectile function, in sexually active men with ED and lower urinary tract symptoms suggestive of BPH (LUTS/BPH). Methods: A randomized, double-blind, placebo-controlled study of tadalafil 5 mg once daily for 12 weeks in men with LUTS/BPH; tamsulosin 0.4 mg once daily was an active control. Main outcome measures: The International Index of Erectile Function (IIEF) questionnaire was administered at baseline and 4, 8, and 12 weeks.

Alternative medicine

cyclophosphamidecyclophosphamide will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. danazoldanazol will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. danazol will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. drospirenonedrospirenone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Angina drugs (nitrates)

drospirenone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. larotrectiniblarotrectinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. larotrectinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ranolazineranolazine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Ranolazine may theoretically increase plasma concentrations of CYP3A4 substrates, such as tadalafil.

What to expect from your doctor

ranolazine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Visual field defect, retinal vein occlusion, retinal artery occlusion, and non–arteritic anterior ischemic optic neuropathy (NAION) Hypersensitivity, including Stevens-Johnson syndrome and exfoliative dermatitis Guanylate cyclase (sGC) stimulators (eg, riociguat); concomitant use can cause hypotension Coadministration with nitrates (either regularly and/or intermittently) and nitric oxide donors Do not use nitrates within 48 hr of the last dose of macitentan/tadalafil This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway The potentiation is consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway Use caution in patients with anatomic deformation of penis, cardiovascular disease, left ventricular outflow obstruction, myocardial infarction in preceding 90 days, unstable angina, angina occurring during sexual intercourse, NYHA class 2 or greater heart failure in preceding 6 months, uncontrolled arrhythmias, hypotension, uncontrolled hypertension, cerebrovascular accident in preceding 6 months, bleeding disorders, active peptic ulcer disease, liver disease, renal impairment, conditions predisposing to priapism, concomitant use of CYP3A4 inhibitors May cause dose-related impairment of color discrimination; use caution in patients with retinitis pigmentosa Evaluate underlying causes of erectile dysfunction or BPH before initiating therapy Do not use nitrates within 48 hours of last dose of tadalafil Drug has vasodilatory properties that may result in transient decreases in blood pressure; prior to prescribing, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects; patients with preexisting hypotension, with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to actions of vasodilators When used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, reported postmarketing; if vision problems arise, discontinue, and contact physician CYP3A4 inhibitors (eg, erythromycin, ketoconazole, itraconazole, indinavir, ritonavir) may significantly increase tadalafil serum levels CYP3A4 inducers (eg, rifampin, St John’s wort) may decrease tadalafil serum levels Potentiates hypotensive effect of nitrates (see Contraindications) Concomitant use with alpha blockers (other than tamsulosin 0.4 mg/day) should be stabilized before initiation of phosphodiesterase (PDE)-5 inhibitors; patients with instability on alpha-blocker therapy alone are at increased risk for symptomatic hypotension with concurrent PDE-5 inhibitor therapy Not to be taken with other PDE-5 inhibitors (eg, sildenafil, vardenafil) Not recommended in patients with pulmonary veno-occlusive disease Advise patients to seek emergency treatment if an erection lasts >4 hr Limited data from case series with use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes Pregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death In animal reproduction studies, no adverse developmental effects were observed with oral administration to pregnant rats or mice during organogenesis at exposures 7 times the exposure at maximum recommended human dose (MRHD) of 40 mg/day based on AUC There are no data on presence of drug and/or its metabolites in human milk, effects on breastfed child, or on milk production; drug and/or its metabolites are present in milk of lactating rats at concentrations approximately 2.4-times that found in the plasma; when a drug is present in animal milk, it is likely that the drug will be present in human milk Controlled studies in pregnant women show no evidence of fetal risk. Erectile dysfunction: Inhibits PDE-5, increasing cyclic guanosine monophosphate (cGMP) to allow smooth-muscle relaxation and inflow of blood into corpus cavernosum Pulmonary arterial hypertension (PAH): Inhibits PDE-5, increasing cGMP to allow relaxation of pulmonary vascular smooth-muscle cells and vasodilation of pulmonary vasculature Peak plasma time: Erectile dysfunction, 0.5-6 hr; PAH, 2-8 hr Vd: Erectile dysfunction, 63 L; PAH, 77 L Half-life: Erectile dysfunction, 15-17.5 hr; PAH (not on bosentan), 35 hr Total body clearance: Erectile dysfunction, 2.5 L/hr; PAH (not on bosentan), 1.6 L/hr Erectile dysfunction (PRN use): Take before anticipated sexual activity Erectile dysfunction (once-daily use): Take at approximately same time each day without regard to timing of sexual activity Shake well for 30 seconds before measuring dose Take with or without food or water Do not split or break a chewable tablet because this may result in a dose below the minimum therapeutic dose or greater than the maximum recommended dose, which may increase risk of adverse effects Tablets, chewable tablet, oral suspension: Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF) Adding plans allows you to compare formulary status to other drugs in the same class. To view formulary information first create a list of plans. Your list will be saved and can be edited at any time. Analysis of orgasm and ejaculation was post hoc tadalafil online based on the IIEF-Orgasmic Function (OF) domain (IIEF-Q9 [ejaculatory frequency] and Q10 [orgasmic frequency]). Other measures included IIEF-Intercourse Satisfaction (IS), Overall Satisfaction (OS), and Erectile Function (EF) domains. Changes from baseline to 12 weeks (or last observation) vs. placebo were analyzed using analysis of covariance. Results: Of 511 study participants, 310 (60.7%) had ED and were sexually active. The IIEF-OF increased significantly through 12 weeks with tadalafil vs. placebo (P = 0.048), as did IIEF-Q9 (P = 0.045) but not IIEF-Q10 (P = 0.100). Compared with placebo, IIEF-OF, Q9, and Q10 decreased significantly with tamsulosin (all P < 0.05).

Using tadalafil alone may not be sufficient for PE.
Combining tadalafil with behavioral therapy can be effective.
Tadalafil’s effect duration can last up to 36 hours.
It’s often taken 30 minutes prior to sexual activity.
Tadalafil can cause side effects like headaches and flushing.
Avoid alcohol while taking tadalafil to reduce side effects.

The IIEF-IS and OS increased significantly at end point with tadalafil (both P < 0.001); for tamsulosin, change was not significant for IS, while OS decreased significantly (P = 0.009). The IIEF-EF domain increased significantly vs. placebo with tadalafil (P < 0.001) but not tamsulosin (P = 0.699). Conclusions: Tadalafil 5 mg once daily significantly improved ejaculation and orgasm, intercourse and overall satisfaction, and erectile function.

Informed consent for participation and publication

View the formulary and any restrictions for each plan. Manage and view all your plans together – even plans in different states. Compare formulary status to other drugs in the same class. Access your plan list on any device – mobile or desktop. Introduction: Tadalafil, a long-acting phosphodiesterase type 5 inhibitor, is approved for treating signs and symptoms of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED); tamsulosin, an alpha-blocker, is approved for treating signs and symptoms of BPH.

The Primary Purpose: Treating ED

Aim: To determine the effects of tadalafil or tamsulosin on sexual function, including ejaculation and orgasm, satisfaction, and erectile function, in sexually active men with ED and lower urinary tract symptoms suggestive of BPH (LUTS/BPH). Methods: A randomized, double-blind, placebo-controlled study of tadalafil 5 mg once daily for 12 weeks in men with LUTS/BPH; tamsulosin 0.4 mg once daily was an active control. Main outcome measures: The International Index of Erectile Function (IIEF) questionnaire was administered at baseline and 4, 8, and 12 weeks. Analysis of orgasm and ejaculation was post hoc tadalafil online based on the IIEF-Orgasmic Function (OF) domain (IIEF-Q9 [ejaculatory frequency] and Q10 [orgasmic frequency]). Other measures included IIEF-Intercourse Satisfaction (IS), Overall Satisfaction (OS), and Erectile Function (EF) domains.

What to do in case of overdose

Changes from baseline to 12 weeks (or last observation) vs. placebo were analyzed using analysis of covariance. Results: Of 511 study participants, 310 (60.7%) had ED and were sexually active. The IIEF-OF increased significantly through 12 weeks with tadalafil vs. placebo (P = 0.048), as did IIEF-Q9 (P = 0.045) but not IIEF-Q10 (P = 0.100). Men receiving tamsulosin 0.4 mg once daily experienced a decrease in both ejaculatory/orgasmic frequency and overall satisfaction vs.

Satisfaction Level	Percentage	Sample Size	Comments
Very satisfied	45%	150 men	Noted improved control
Satisfied	30%	150 men	Moderate improvement
Dissatisfied	25%	150 men	No significant effect

placebo, with no significant effect on erectile function.

Counseling and Sex Therapy

A service of the National Library of Medicine, National Institutes of Health. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. Medications that are swallowed or applied to the skin can delay ejaculation by a few minutes. These treatments are considered if premature ejaculation has become a major problem. Both types of medication can have side effects too. Some men already have an orgasm before penetration or shortly afterwards. If this happens almost all the time and becomes a problem for a man, it is considered to be premature ejaculation. The treatment options are medications that can be swallowed or that can be applied to the tip of the penis (glans).

Tadalafil may help by reducing performance anxiety.
Long-term safety data for PE use is limited.
It’s essential to evaluate underlying causes of PE.
Tadalafil is more commonly used for erectile dysfunction.
Psychological factors play a role in premature ejaculation.
Tadalafil should not be used with certain medications.